deltatrials
Completed PHASE1/PHASE2 NCT00003394

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Phase I/II Study of Weekly Intravenous Estramustine Phosphate in Combination With Paclitaxel and Carboplatin in Patients With Advanced Prostate Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Prostate Cancer
Interventions carboplatin endocrine-modulating drug therapy estramustine phosphate sodium goserelin acetate leuprolide acetate paclitaxel
Updated 5 times since 2017 Last updated: Jun 20, 2013 Started: Apr 30, 1998 Primary completion: Apr 30, 2003 Completion: Apr 30, 2003

A PHASE1/PHASE2 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 5 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Apr 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States